{"id":382277,"date":"2025-09-11T08:10:18","date_gmt":"2025-09-11T08:10:18","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/382277\/"},"modified":"2025-09-11T08:10:18","modified_gmt":"2025-09-11T08:10:18","slug":"lue-va-se-pencher-sur-une-nouvelle-indication-pour-lenhertu-dastrazeneca","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/382277\/","title":{"rendered":"L&rsquo;UE va se pencher sur une nouvelle indication pour l&rsquo;Enhertu d&rsquo;AstraZeneca"},"content":{"rendered":"<p>        &#13;<br \/>\n            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/09\/769-c.jpg\" alt=\"bourse AstraZeneca PLC\"\/><\/p>\n<p>(Zonebourse.com) &#8211; AstraZeneca a annonc\u00e9 mercredi que la demande de variation de type II d\u00e9pos\u00e9e pour une nouvelle indication d&rsquo;Enhertu, le conjugu\u00e9 anticorps-m\u00e9dicament qu&rsquo;il d\u00e9veloppe avec Daiichi Sankyo, dans le traitement des tumeurs solides m\u00e9tastatiques HER2-positives avait \u00e9t\u00e9 valid\u00e9e par l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA), o\u00f9 le dossier est d\u00e9sormais en cours d&rsquo;\u00e9valuation.<\/p>\n<p>La validation de l&rsquo;EMA porte sur les formes non op\u00e9rables ou m\u00e9tastatiques des formes dites &lsquo;HER2 positives&rsquo; des tumeurs solides chez les patients ayant d\u00e9j\u00e0 re\u00e7u un traitement et qui ne disposent pas d&rsquo;alternatives th\u00e9rapeutiques satisfaisantes.<\/p>\n<p>Dans l&rsquo;Union europ\u00e9enne, Enhertu est actuellement commercialis\u00e9 dans le traitement du cancer du sein HER2 positif non op\u00e9rable et m\u00e9tastatique chez les patients ayant d\u00e9j\u00e0 re\u00e7u une th\u00e9rapie anti-HER2<\/p>\n<p>La validation de sa variation de type II va marquer le d\u00e9but du processus d&rsquo;examen scientifique par le Comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP).<\/p>\n<p>S&rsquo;il devait \u00eatre autoris\u00e9, Enhertu deviendrait le premier anticorps conjugu\u00e9 et le premier m\u00e9dicament visant directement la prot\u00e9ine HER2 \u00e0 \u00eatre approuv\u00e9 en Europe dans le traitement des tumeurs solides.<\/p>\n<p>Copyright \u00a9 2025 Zonebourse.com &#8211; All rights reserved.<\/p>\n<p>&#13;<br \/>\n            &#13;<\/p>\n<p>Vous avez aim\u00e9 cet article ? Partagez-le avec vos amis avec les boutons ci-dessous.<\/p>\n<p>        <a target=\"_blank\" title=\"Twitter\" href=\"https:\/\/twitter.com\/share?url=https:\/\/www.abcbourse.com\/marches\/l-ue-va-se-pencher-sur-une-nouvelle-indication-pour-l-enhertu-d-astrazeneca_674248&amp;text=L&#039;UE va se pencher sur une nouvelle indication pour l&#039;Enhertu d&#039;AstraZeneca&amp;via=abcbourse\" rel=\"nofollow noopener\">&#13;<br \/>\n            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/04\/share_twitter.png\" class=\"mr10\" alt=\"Twitter\"\/>&#13;<br \/>\n        <\/a><br \/>\n        <a target=\"_blank\" title=\"Facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.abcbourse.com\/marches\/l-ue-va-se-pencher-sur-une-nouvelle-indication-pour-l-enhertu-d-astrazeneca_674248&amp;t=L&#039;UE va se pencher sur une nouvelle indication pour l&#039;Enhertu d&#039;AstraZeneca\" rel=\"nofollow noopener\">&#13;<br \/>\n            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/04\/share_fb.png\" alt=\"Facebook\" class=\"mr10\"\/>&#13;<br \/>\n        <\/a><br \/>\n        <a target=\"_blank\" title=\"Linkedin\" href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https:\/\/www.abcbourse.com\/marches\/l-ue-va-se-pencher-sur-une-nouvelle-indication-pour-l-enhertu-d-astrazeneca_674248&amp;title=L&#039;UE va se pencher sur une nouvelle indication pour l&#039;Enhertu d&#039;AstraZeneca\" rel=\"nofollow noopener\">&#13;<br \/>\n            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/04\/share_linkedin.png\" alt=\"Linkedin\" class=\"mr10\"\/>&#13;<br \/>\n        <\/a><br \/>\n        <a target=\"_blank\" title=\"Envoyer par mail\" href=\"https:\/\/www.abcbourse.com\/marches\/mailto:?subject=L\" ue=\"\" va=\"\" se=\"\" pencher=\"\" sur=\"\" une=\"\" nouvelle=\"\" indication=\"\" pour=\"\" l=\"\" d=\"\" rel=\"nofollow noopener\">&#13;<br \/>\n            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/fr\/wp-content\/uploads\/2025\/04\/share_email.png\" alt=\"email\"\/>&#13;<br \/>\n        <\/a><br \/>\n    <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"&#13; (Zonebourse.com) &#8211; AstraZeneca a annonc\u00e9 mercredi que la demande de variation de type II d\u00e9pos\u00e9e pour une&hellip;\n","protected":false},"author":2,"featured_media":382278,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1586],"tags":[11,1777,674,1779,1011,27,12,25,1778,364],"class_list":{"0":"post-382277","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-actualites","9":"tag-eu","10":"tag-europe","11":"tag-european-union","12":"tag-fr","13":"tag-france","14":"tag-news","15":"tag-republique-francaise","16":"tag-ue","17":"tag-union-europeenne"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115184653997266941","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/382277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=382277"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/382277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/382278"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=382277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=382277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=382277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}